P48.06 Lurbinectedin in Combination with Pembrolizumab for ...

P48.06 Lurbinectedin in Combination with Pembrolizumab for Patients with Relapsed Small Cell Lung Cancer. LUPER Clinical Trial · Introduction. Small cell lung ...

lurbinectedin in combination with pembrolizumab for the treatment of pts with SCLC in second line after relapse or progressive disease. The phase I stage is ...

P48.06 Lurbinectedin in Combination with Pembrolizumab for ...

Request PDF | On Mar 1, 2021, M.J. De Miguel Luken and others published P48.06 Lurbinectedin in Combination with Pembrolizumab for Patients with Relapsed ...

P48.06 Lurbinectedin in Combination with Pembrolizumab ... - ebsco

P48.06 Lurbinectedin in Combination with Pembrolizumab for Patients with Relapsed Small Cell Lung Cancer. LUPER Clinical Trial. Authors. De Miguel Luken, M.J. ...

Lurbinectedin in combination with pembrolizumab in relapsed SCLC

The combination demonstrated efficacy with manageable safety, suggesting its potential as a second-line therapy for SCLC and warranting further ...

IASLC 2020 World Conference on Lung Cancer: LUPER initiated ...

During the Phase I trial, the LUPER study will evaluate the maximum tolerated dose of lurbinectedin in combination with pembrolizumab, in order ...

Lurbinectedin in combination with pembrolizumab in relapsed SCLC

Andrea Ardizzoni, MD, PhD, University of Bologna, Bologna, Italy, shares findings from the LUPER study (NCT04358237) which aimed to explore ...

Current and Emerging Treatment Options for Patients With Relapsed ...

Lurbinectedin (PM01183) Combined With Pembrolizumab in. Small Cell Lung Cancer. Pembrolizumab plus lurbinectedin. Checkpoint inhibitor plus alkylating agent.

Updated Results from Phase 1/2 Clinical Trial | Request PDF

P48.06 Lurbinectedin in Combination with Pembrolizumab for Patients with Relapsed Small Cell Lung Ca... March 2021 · Journal of Thoracic Oncology. M.J. De ...

ESMO Congress 2023 | OncologyPRO

1989MO - Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study ; Citation. Annals of ...

Current and Emerging Treatment Options for Patients With Relapsed ...

This is a chemotherapy drug called lurbinectedin. The other study results suggested that some of the drugs investigated may also help to control small-cell lung ...

Immunotherapy for Small Cell Lung Cancer - Hematology & Oncology

Studies are currently investigating combinations of lurbinectedin plus pembrolizumab ... P48.03]. J Thorac Oncol. 2021;16(3)(suppl):S500. 29. Rudin CM ...

Preliminary Results Show Second-line Lurbinectedin Plus ...

Preliminary findings of data from the phase 1/2 LUPER study demonstrate that treatment with lurbinectedin combined with pembrolizumab ...

lurbinectedin in combination with pembrolizumab in relapsed SCLC

LUPER: lurbinectedin in combination with pembrolizumab in relapsed SCLC · VJOncology · Phase II PATHWay: adjuvant pembrolizumab in patients with ...

LUPER Study Results: Lurbinectedin + Pembrolizumab in Relapsed ...

... lurbinectedin plus the anti–PD-1 pembrolizumab combination regimen showed promising antitumor activity with a manageable safety profile in patients with ...

Lurbinectedin (PM01183) Combined With Pembrolizumab in Small ...

The presentation...concludes that the combination of lurbinectedin and pembrolizumab is an effective second-line treatment for SCLC in patients who did not ...

Antonio Calles, MD, Highlights Promising Preliminary Activity of ...

Early results from the phase 1/2 LUPER study indicated that lurbinectedin in combination with pembrolizumab demonstrated no unexpected ...